Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists.
The antiparkinsonian activity of several dopamine agonists was investigated in an animal model and clinically in parkinsonian patients. The semisynthetic ergoline, pergolide, the partial ergoline, LY 141865 and the 8-alpha-aminoergoline, CU 32-085 were found to be effective antitremor agents in monkeys with ventromedial tegmental lesions. The administration of pergolide or LY 141865 results in a relief of tremor with a concomitant occurrence of severe abnormal involuntary movements, while the administration of CU 32-085 results in a relief of tremor with the occurrence of only minor abnormal involuntary movements. Clinical studies have revealed that pergolide is an effective drug in patients with advanced Parkinson's disease, and it reduces the "on-off" phenomena. The possible regulation of dopamine neurotransmission by the norepinephrine neuronal systems was reviewed. Preliminary data suggest that clonidine may interact with presynaptic dopamine receptors.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D004873:Ergolines / Q000627:therapeutic use*; D000882:Haplorhini; D006801:Humans; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide; D019257:Quinpirole; D051381:Rats
D000316:Adrenergic alpha-Agonists; D004873:Ergolines; D019257:Quinpirole; D010479:Pergolide; C031649:mesulergine; D004298:Dopamine; D009638:Norepinephrine